摘要
目的:比较蛋白酶体抑制剂PS-341处理多发性骨髓瘤细胞U266前后蛋白质组的差异,探究PS-341潜在的药物靶点,为多发性骨髓瘤的临床治疗提供理论依据。方法:用蛋白酶体抑制剂PS-341处理骨髓瘤细胞U266,应用双向凝胶电泳技术分离PS-341处理前后的U266细胞的蛋白质,Im-ageMaster 2D Platinum图像分析软件识别药物处理前后U266细胞的差异表达蛋白质点,基质辅助激光解吸电离飞行时间质谱(MALDI-TOF-MS)鉴定差异表达的蛋白质。Western印迹法检测差异蛋白质BAG-2在药物处理前后U266细胞中的表达水平。结果:建立了PS-341处理前后U266细胞蛋白质的双向凝胶电泳图谱,找到55个差异表达的蛋白质点,鉴定了31个差异表达的蛋白质,有27个蛋白质在PS-341处理后下调。Western印迹分析证实BAG-2在药物处理前后U266细胞中的表达水平存在差异。结论:处理后下调的一些蛋白可能是蛋白酶体抑制剂PS-341潜在的药物靶标。
Objective To compare the proteome difference between multiple myeloma cell line U266 cells treated and untreated with PS-341,to investigate the potential drug targets,and to provide theoretical evidence for clinical therapy of multiple myeloma.Methods Two-dimensional gel electrophoresis（2-DE） was performed to separate proteins from treated and untreated U266 cells with proteasome inhibitor PS-341.ImageMaster 2D Platinum software was used to analyze 2-DE image,and matrix-assisted laser desorption/ionization time of flight mass spectrometry（MALDI-TOF-MS） was used to identify the differentially expressed proteins.The expression levels of differential protein BAG-2 in the 2 groups of U266 cells lines were detected by Western blot.Results The 2-DE reference pattern of treated and untreated U266 cells with PS-341 was established.A total of 31 differential proteins were identified by MALDI-TOF-MS,27 of which were down-regulated after PS-341 treatment.The differential expression level of BAG-2 in the 2 groups of U266 cells was confirmed by Western blot.Conclusion Some down-regulated proteins may be the potential drug targets of proteasome inhibitor PS-341.
出处
《中南大学学报（医学版）》
CAS
CSCD
北大核心
2010年第8期784-791,共8页
Journal of Central South University ：Medical Science
关键词
PS-341
多发性骨髓瘤
双向凝胶电泳
质谱
药物靶标
PS-341
multiple myeloma
2-dimensional gel electrophoresis
mass spectrome-try
drug target
